Treats moderate to severe plaque psoriasis. NDA 209483, held by Primus Pharms. Clobetasol Propionate.
As of Nov 13, 2026, NDA 209483 (Impoyz), held by Primus Pharms, was first approved by FDA on Nov 28, 2017, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Clobetasol Propionate Cream is a corticosteroid indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 28, 2017 | Original applicationNew formulation or manufacturer · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Impoyz0.025% · cream;topical | Clobetasol Propionate | RxReference drug |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
